tbuckley/cabot-search huggingface dataset:
Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose
Authors: Wei Hao, Steven Gitelman, Linda A. DiMeglio, David Boulware, Carla J. Greenbaum
Journal: Diabetes Care (2016)

We aimed to describe the natural history of residual insulin secretion in Type 1 Diabetes TrialNet participants over 4 years from diagnosis and relate this to previously reported alternative clinical measures reflecting β-cell secretory function.Data from 407 subjects from 5 TrialNet intervention studies were analyzed. All subjects had baseline stimulated C-peptide values of ≥0.2 nmol/L from mixed-meal tolerance tests (MMTTs). During semiannual visits, C-peptide values from MMTTs, HbA1c, and insulin doses were obtained.The percentage of individuals with stimulated C-peptide of ≥0.2 nmol/L or detectable C-peptide of ≥0.017 nmol/L continued to diminish over 4 years; this was markedly influenced by age. At 4 years, only 5% maintained their baseline C-peptide secretion. The expected inverse relationships between C-peptide and HbA1c or insulin doses varied over time and with age. Combined clinical variables, such as insulin-dose adjusted HbA1c (IDAA1C) and the relationship of IDAA1C to C-peptide, also were influenced by age and time from diagnosis. Models using these clinical measures did not fully predict C-peptide responses. IDAA1C ≤9 underestimated the number of individuals with stimulated C-peptide ≥0.2 nmol/L, especially in children.Current trials of disease-modifying therapy for type 1 diabetes should continue to use C-peptide as a primary end point of β-cell secretory function. Longer duration of follow-up is likely to provide stronger evidence of the effect of disease-modifying therapy on preservation of β-cell function.
Bilateral Coronary Artery Fistulas With Multiple Sites of Drainage
Authors: Keiichi Yasuma, Shigeo Takata, Toyoshi Yuasa, Masayuki Takamura, Hideo Nagai, Satoru Sakagami, Ken-ichi Kobayashi
Journal: Circulation (1998)

A 49-year-old woman presented with bilateral coronary fistulas with multiple sites of drainage. She had been referred to hospital for evaluation of a cardiac murmur, and a coronary arteriogram revealed multiple coronary fistulas. One fistula originated from the proximal part of the left anterior descending coronary artery and connected to the main pulmonary artery. Three coronary artery fistulas arised from a conal branch of the right coronary artery and drained into the main pulmonary artery, the right atrium and the great cardiac vein. This is the first reported case of bilateral coronary fistulas with multiple sites of drainage. (Jpn Circ J 1998; 62: 783 - 784)
Epidemiology of tetanus in Italy in years 1971-2000
Authors: B Pedalino, B Cotter, M L Ciofi Degli Atti, D Mandolini, S Parroccini, S Salmaso
Journal: Eurosurveillance (2002)

The incidence of reported tetanus in Italy decreased from 0.5/100,000 in the 1970s to 0.2/100,000 in the 1990 s. During this period of time, the case-fatality ratio decreased from 68% to 39%. Italy has the highest reported number of tetanus cases in European countries. Elderly women are the most affected: the proportion of women aged over 64 years among cases has increased from 60% in the 1970s to 76% in the 1990s. Vaccination campaigns need to be conducted to target this group, and the surveillance of tetanus has to be improved to identify additional groups of population at risk.
Effects of a program for evaluating child psychiatry fellows
Authors: C M Pfeifer, G A Rogeness, R L Rubin, A C Serrano
Journal: American Journal of Psychiatry (1979)

The authors describe their experience with the implementation of a systematic evaluation of child psychiatry fellows and adult psychiatry residents rotating through a child psychiatry program. They found that the semiannual evaluations not only defined the competence of fellows and residents but also enhanced the program by pointing out areas of weakness. The evaluation process had many other beneficial effects on the program, the faculty, the child psychiatry fellows, and the adult psychiatry residents.
Case 3-1978
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Andrew L. Warshaw, James J. Galdabini
Journal: New England Journal of Medicine (1978)

Presentation of CaseA 77-year-old man was admitted to the hospital because of bleeding per rectum.He was apparently well until two weeks before admission, when he experienced nausea, vomiting and persistent hiccupping. Five days before entry he passed an unknown volume of fresh blood per rectum and began to have low-back pain; he was taken by friends to another hospital.The patient took large amounts of a proprietary aspirin compound because of "arthritis." There was no history of abdominal pain or previous gastrointestinal disease.The temperature was 36.1°C, the pulse 140 and irregular, and the respirations 22. The blood . . .
Amorphous Silica: A New Antioxidant Role for Rapid Critical‐Sized Bone Defect Healing
Authors: Azhar Ilyas, Tetsuro Odatsu, Ami Shah, Felipe Monte, Harry K. W. Kim, Philip Kramer, Pranesh B. Aswath, Venu G. Varanasi
Journal: Advanced Healthcare Materials (2016)

Traumatic fractures cause structurally unstable sites due to severe bone loss. Such fractures generate a high yield of reactive oxygen species (ROS) that can lead to oxidative stress. Excessive and prolonged ROS activity impedes osteoblast differentiation and instigates long healing times. Stimulation of antioxidants such as superoxide dismutase (SOD1), are crucial to reduce ROS, stimulate osteogenesis, and strengthen collagen and mineral formation. Yet, no current fixative devices have shown an ability to enhance collagen matrix formation through antioxidant expression. This study reports plasma‐enhanced chemical vapor deposition based amorphous silicon oxynitride (Si(ON)x) as a potential new fracture healing biomaterial that adheres well to the implant surface, releases Si +4 to enhance osteogenesis, and forms a surface hydroxyapatite for collagen mineral attachment. These materials provide a sustained release of Si +4 in physiological environment for extended times. The dissolution rate partially depends on the film chemistry and can be controlled by varying O/N ratio. The presence of Si +4 enhances SOD1, which stimulates other osteogenic markers downstream and leads to rapid mineral formation. In vivo testing using a rat critical‐sized calvarial defect model shows a more rapid bone‐regeneration for these biomaterials as compared to control groups, that implies the clinical significance of the presented biomaterial.
Mitochondrial complex I dysfunction and altered NAD(P)H kinetics in rat myocardium in cardiac right ventricular hypertrophy and failure
Authors: Rob C.I. Wüst, Heder J. de Vries, Liesbeth T. Wintjes, Richard J. Rodenburg, Hans W.M. Niessen, Ger J.M. Stienen
Journal: Cardiovascular Research (2016)

Aims In cardiac hypertrophy (CH) and heart failure (HF), alterations occur in mitochondrial enzyme content and activities but the origin and implications of these changes for mitochondrial function need to be resolved. Methods and results Right ventricular CH or HF was induced by monocrotaline injection, which causes pulmonary artery hypertension, in rats. Results were compared with saline injection (CON). NAD(P)H and FAD autofluorescence were recorded in thin intact cardiac trabeculae during transitions in stimulation frequency, to assess mitochondrial complex I and complex II function, respectively. Oxygen consumption, mitochondrial morphology, protein content, and enzymatic activity were assessed. NAD(P)H autofluorescence upon an increase in stimulation frequency showed a rapid decline followed by a slow recovery. FAD autofluorescence followed a similar time course, but in opposite direction. The amplitude of the early rapid change in NAD(P)H autofluorescence was severely depressed in CH and HF compared with CON. The rapid changes in FAD autofluorescence in CH and HF were reduced to a lesser extent. Complex I-coupled respiration showed an ∼3.5-fold reduction in CH and HF; complex II-coupled respiration was depressed two-fold in HF. Western blot analyses revealed modest reductions in complex I protein content in CH and HF and in complex I activity in supercomplexes in HF. Mitochondrial volume density was similar, but mitochondrial remodelling was evident from changes in ultrastructure and fusion/fission indices in CH and HF. Conclusion These results suggest that the alterations in mitochondrial function observed in right ventricular CH and HF can be mainly attributed to complex I dysfunction.
Investigation d'une épidémie inexpliquée de troubles cutanés dans une clinique pénitentiaire aux Pays-Bas en 2002
Authors: J G Breugelmans, A Bosman, A. K van der Heide, E. Y.R Roeleveld-Kuijper, D P Bruynzeel
Journal: Eurosurveillance (2003)

Une flambee inexpliquee de troubles cutanes (papules ou pustules avec prurit) est apparue dans une clinique penitentiaire aux Pays-Bas en octobre-decembre 2002. L'etude descriptive de cohorte montre qu'elle pourrait etre associee a un lot perime d'aleses jetables, avec un taux d'attaque global de 30% dans la population etudiee (n = 118). Aucun nouveau cas n'a ete rapporte depuis le retrait du lot expire.
P-283 Paclitaxel plus valproic acid versus paclitaxel alone as second or third line therapy for advanced gastric cancer: a randomized phase 2 trial
Authors: J. Kinoshita, S. Fushida, M. Kaji, K. Oyama, Y. Hirono, H. Nezuka, T. Takeda, T. Tsukada, S. Ohyama, T. Fujimura, T. Ohta
Journal: Annals of Oncology (2016)
Rectal Carcinoma on 68Ga-PSMA PET/CT
Authors: Yi-Tung Tom Huang, William Fong, Paul Thomas
Journal: Clinical Nuclear Medicine (2015)

We report on a case of biopsy-proven and MRI-staged rectal carcinoma with avid prostate-specific membrane antigen (prostate-specific membrane antigen) uptake on Ga PET/CT as part of the workup for synchronous prostate cancer. This case adds to the growing number of observational reports on the presence of significant nonprostatic prostate-specific membrane antigen activity in malignant tumors and highlights the need for careful interpretation of unsuspected sites.
Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy
Authors: Hatem A.F.M. Hassan, Lesley Smyth, Julie T.-W. Wang, Pedro M. Costa, Kulachelvy Ratnasothy, Sandra S. Diebold, Giovanna Lombardi, Khuloud T. Al-Jamal
Journal: Biomaterials (2016)

Although anti−cancer immuno−based combinatorial therapeutic approaches have shown promising results, efficient tumour eradication demands further intensification of anti−tumour immune response. With the emerging field of nanovaccinology, multi−walled carbon nanotubes (MWNTs) have manifested prominent potentials as tumour antigen nanocarriers. Nevertheless, the utilization of MWNTs in co−delivering antigen along with different types of immunoadjuvants to antigen presenting cells (APCs) has not been investigated yet. We hypothesized that harnessing MWNT for concurrent delivery of cytosine−phosphate−guanine oligodeoxynucleotide (CpG) and anti-CD40 Ig (αCD40), as immunoadjuvants, along with the model antigen ovalbumin (OVA) could potentiate immune response induced against OVA−expressing tumour cells. We initially investigated the effective method to co−deliver OVA and CpG using MWNT to the APC. Covalent conjugation of OVA and CpG prior to loading onto MWNTs markedly augmented the CpG−mediated adjuvanticity, as demonstrated by the significantly increased OVA−specific T cell responses in vitro and in C57BL/6 mice. αCD40 was then included as a second immunoadjuvant to further intensify the immune response. Immune response elicited in vitro and in vivo by OVA, CpG and αCD40 was significantly potentiated by their co−incorporation onto the MWNTs. Furthermore, MWNT remarkably improved the ability of co−loaded OVA, CpG and αCD40 in inhibiting the growth of OVA−expressing B16F10 melanoma cells in subcutaneous or lung pseudo−metastatic tumour models. Therefore, this study suggests that the utilization of MWNTs for the co−delivery of tumour−derived antigen, CpG and αCD40 could be a competent approach for efficient tumours eradication.
Targeting histone deacetylase to overcome resistance of B-RAF<sup>V600E</sup> melanoma cells to apoptosis.
Authors: P. Hersey
Journal: Journal of Clinical Oncology (2011)

8516 Background: Limited durability of responses of melanomas carrying active mutations in B-RAF to mutant B-RAF-specific inhibitors remains a major obstacle for curative treatment of the disease by the inhibitors. Methods: Our previous studies on B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the inhibitor PLX4720 (PLX-selected cells) have shown that sensitivity to induction of apoptosis may be a major determinant of long-term responses of B-RAFV600E melanomas. Results: Here we show that histone deacetylase inhibitors can partially overcome resistance of PLX4720-selected cells to apoptosis by up-regulation of caspases and Bim. PLX-selected melanoma cells appeared cross-resistant to diverse apoptotic stimuli, such as the DNA-damaging drug cisplatin, the microtubule-targeting agent docetaxel, the proteasome inhibitor bortezomib, and the death ligand TRAIL. This was associated with decreased expression of key components of apoptotic pathways including multiple BH3-only proteins and caspases. However, treatment with the histone deacetylase inhibitor SAHA or sodium butyrate induced markedly higher levels of apoptosis in PLX4720-selected cells than their parental counterparts. This was caused by restoration of the expression of caspases, and in particular, Bim, as inhibition of caspases or knockdown of Bim by siRNA blocked induction of apoptosis in PLX-selected cells. In addition, combinations of SAHA and PLX4720 synergistically induced apoptosis in B-RAFV600E melanoma cells naïve to the inhibitor. Conclusions: Taken together, these results indicate that B-RAFV600E melanoma cells that are resistant to selective BRAF inhibitors may also be resistant to a number of other agents used to treat melanoma. Addition of histone deacetylase inhibitors however, may be effective in overcoming resistance of the cells to selective BRAF inhibitors and other apoptosis inducing agents.
SWOG S0809: A phase II trial of adjuvant capecitabine (cap)/gemcitabine (gem) followed by concurrent capecitabine and radiotherapy in extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBCA).
Authors: Edgar Ben-Josef, Katherine Guthrie, Anthony B. El-Khoueiry, Christopher L. Corless, Mark Zalupski, Andrew M. Lowy, Charles R. Thomas, Steven R. Alberts, Laura A. Dawson, Kenneth C. Micetich, Melanie B. Thomas, Abby B. Siegel, Charles David Blanke
Journal: Journal of Clinical Oncology (2014)

4030 Background: The role of adjuvant therapy after resection of EHCC or GBCA is unknown. S0809 was designed to estimate the stratum-specific (R0 and R1) and overall 2-year survival (OS), overall disease-free survival (DFS), local relapse (LR), and toxicity in patients (pts) treated with this adjuvant regimen. Methods: Eligibility included tissue diagnosis of EHCC or GBCA s/p radical resection, pT2-4, N+ or R1, M0, and PS 0-1. Pts received 4 cycles of gem (1 g/m2 IV, d1, d8) and cap (1500 mg/m2/d, days 1-14) q 21 days followed by concurrent cap (1330 mg/m2/d) and radiation (45 Gy to regional lymphatics and 54-59.4 Gy to the tumor bed). A total of 80 evaluable pts were needed; results would be considered promising if the 95% confidence interval (CI) for 2-year OS excluded a rate <45% and if the stratum specific point estimates were ≥65% for R0 and ≥45% for R1. Central pathology and radiation therapy reviews were performed. Results: 79 evaluable pts (54 R0, 25 R1) were registered; median age 62 yrs, 52% women, 62% EHCC and 38% GBCA. 86% of pts completed planned therapy; 3 pts discontinued therapy due to adverse effects (AEs). Grade 3 and 4 AEs were observed in 53% and 11% of pts. Most common grade 3/4 AEs included neutropenia (44%), hand-foot syndrome (13%), diarrhea (8%), lymphopenia (8%), and leukopenia (6%). There was one death from GI hemorrhage. Median OS was 33 months (33/30 for R0/R1). 12 pts developed LR, of whom 9 had a concurrent distant relapse. 24 patients developed distant-only relapse. Conclusions: This trial establishes the feasibility of adjuvant treatment in EHCC and GBCA and provides critically needed prospective data acquired in a multi-institutional setting. Both efficacy data and completion rate are promising and warrant further investigation in a phase 3 trial. Clinical trial information: NCT00789958. All pts % (95% CI) R0 cohort % (95% CI) R1 cohort % (95% CI) EHCC % (95% CI) GBCA % (95% CI) 2- year OS 62 (50-72) 65 (51-77) 56 (33-74) 66 (50-78) 56 (37-72) 2- year DFS 50 (38-60) 52 (38-65) 44 (23-63) 51 (36-65) 47 (28-63) 2-year LR 12 (5-19) 10 (2-18) 18 (2-33) 11 (2-21) 13 (1-25)
Predicting 30-Day Readmission or Death in Heart Failure—Reply
Authors: Quan L. Huynh, Thomas H. Marwick
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Oral fluoroquinolone treatment was not associated with serious arrhythmia
Authors: Thomas Fekete
Journal: Annals of Internal Medicine (2016)

ACP Journal Club21 June 2016Oral fluoroquinolone treatment was not associated with serious arrhythmiaThomas Fekete, MDThomas Fekete, MDTemple University School of Medicine, Philadelphia, Pennsylvania, USA (T.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2016-164-12-067 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationInghammar M, Svanström H, Melbye M, Pasternak B, Hviid A. Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. BMJ. 2016;352:i843. https://pubmed.ncbi.nlm.nih.gov/26920666Clinical Impact RatingsGIM/FP/GP: Cardiology: Infectious Disease: References1 Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013;368:1704-12. [PMID: 23635050] Google Scholar2 Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881-90. [PMID: 22591294] Google Scholar Author, Article, and Disclosure InformationAuthors: Thomas Fekete, MDAffiliations: Temple University School of Medicine, Philadelphia, Pennsylvania, USA (T.F.)This article was published at Annals.org on 7 June 2016. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 21 June 2016Volume 164, Issue 12Page: JC67KeywordsAntibioticsArrhythmiaCardiovascular therapyCohort studiesDatabasesDrugsFearHeart diseasesOutpatientsPenicillin ePublished: 21 June 2016 Issue Published: 21 June 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Permeability changes in bladder cancer cell gemcitabine due to electromagnetic field.
Authors: Alla Ivanovna Shikhlyarova, Olga Vladimirovna Tarnopolskaya, Alexey N. Shevchenko, Elena V. Filatova
Journal: Journal of Clinical Oncology (2014)

e15524 Background: Improving the efficiency of cancer chemotherapy is largely due to the detailed study of the transport of drugs across the membranes of tumor cells, bioelectric properties that are different from normal. It is known that the membrane potential (MP) is a control parameter of cell activity. In experiments in vitro and in vivo proof of the possibility of increasing the permeability of chemotherapy when exposed to electromagnetic fields (EMF) on the tumor was shown. Aim of this study was to investigate the changes of isolated cells MP of non-muscle invasive bladder cancer when added to the cell suspension of gemcitabine in combination with EMF exposure. Methods: The work was performed on 36 samples from 6 patients 35 - 60 years with non-muscle invasive bladder cancer. After transurethral resection of the pieces of the removed tumor cell suspension was prepared. Cells were stained with voltage- vital fluorochromes and examined under a fluorescence microscope «Axio Imager.M2», Zeiss. Microphotography was performed with color digital camera Axio Cam HR. Used fluorescent probes anion voltage- ANS (1 - anilinonaftalin -8- sulphonate) and cation DCM (4 - (n- dimethylaminostyryl )-1 - methylpyridinium ). Gemcitabine was used in a concentration of 4 mg/ml. The data obtained in cell size and brightness (Br) fluorescence were treated statistically (mean and standard deviation). Based on the average brightness of cells without exposure to the performance of the cells incubated with gemcitabine in combination with EMF (Br0 / Brcytost ; Br0 / Brcytost + EMF). Each sample was measured from 300 to 800 cells. Results: Average MP cells of non-muscle invasive bladder cancer change in the intensity of ANS when adding gemcitabine decreased on average by 2,1 ± 0,3 times, and kept the resulting EMF exposure level values. In contrast, high amplitude value of the average brightness MPA under the influence of electromagnetic fields on cell suspension with gemcitabine was reduced by 40-50%. Conclusions: Findings suggest corrective effect of EMF on the membrane permeability of tumor cells to cytostatic, increasing its bioavailability, characterized by a change in their fluorescence intensity.
Drug company is suspended from UK industry body after “deception on a grand scale”
Authors: Adrian O’Dowd
Journal: BMJ (2016)

The UK subsidiary of a prominent Japanese drug firm has had its membership of the United Kingdom’s industry representative body suspended after what has been described as “deception on a grand scale.”

The Association of the British Pharmaceutical Industry’s one year suspension of Astellas UK, from 24 June, was made because of serious breaches of the association’s code of practice that related to covert attempts to market prostate cancer drugs to doctors.

The decision came after a complaint about an advisory board meeting that was held in Milan in February 2014 and was ruled to be in breach of the code, including of clause 2, which deals with actions likely to bring discredit on, or …
Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia
Authors: Gautam Borthakur, Jorge E. Cortes, Farhad Ravandi, Graciela Nogueras Gonzalez, Rajyalakshmi Luthra, Elias Jabbour, Guillermo Garcia-Manero, Tapan M. Kadia, Joyce Bass, Mark Brandt, Hagop M. Kantarjian
Journal: Blood (2013)